CD366 (TIM3) Monoclonal Antibody (RMT3-23), eBioscience
PRODUCT DETAILS
Host: Rat
Isotype: IgG2a, kappa
Clonality: Monoclonal
Clone: RMT3-23
Reactivity: Ms
Application: Flow Cytometry
Tested Dilution: 1 µg/test
Concentration: 0.5 mg/mL
Storage: 4°C
Formulation: PBS with 0.09% sodium azide; pH 7.2
Purification: Affinity chromatography
Data Sheet: TDS
Specific Information
Description: The RMT3-23 monoclonal antibody reacts with mouse CD366 (TIM3), a Th1-specific cell surface protein. The RMT3-23 antibody reacts with CD366 protein expressed by both BALB/c and C57BL/6 strains of mice. CD366, a type I transmembrane protein, contains an immunoglobulin and a mucin-like domain in its extracellular portion and a tyrosine phosphorylation motif in its cytoplasmic portion. CD366 is expressed selectively by differentiated CD4^+Th1 and CD8^+Tc1 cells, but is absent on CD4^+Th2 and CD8^+Tc2 cells. Other hematopoietic cell types, including naive T cells, B cells, macrophages and dendritic cells, do not express CD366, at least at the protein level. CD366 expression is upregulated at a late stage of T cell differentiation on Th1 cells after 3 rounds of in vitro polarization suggesting a role for this molecule in the transport or effector function of Th1 cells rather than a contribution to T cell differentiation. In an experimental autoimmune encephalomyelitis (EAE) model, CD366 was shown to be expressed on most CD4^+ and CD8^+ T cells in the central nervous system at the onset of clinical signs of disease, while less than 2% of CD4^+ cells in the periphery expressed CD366 after immunization.
RMT3-23 has been shown to have functional activity; blocks DC recognition of apoptotic cells and also induces autoantibody production.
Applications Reported: This RMT3-23 antibody has been reported for use in flow cytometric analysis.
Applications Tested: This RMT3-23 antibody has been tested by flow cytometric analysis of CD366 transfected cells. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Purity: Greater than 90%, as determined by SDS-PAGE.
Aggregation: Less than 10%, as determined by HPLC.
Filtration: 0.2 µm post-manufacturing filtered.
Â
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.Original: $326.00
-70%$326.00
$97.80CD366 (TIM3) Monoclonal Antibody (RMT3-23), eBioscience
PRODUCT DETAILS
Host: Rat
Isotype: IgG2a, kappa
Clonality: Monoclonal
Clone: RMT3-23
Reactivity: Ms
Application: Flow Cytometry
Tested Dilution: 1 µg/test
Concentration: 0.5 mg/mL
Storage: 4°C
Formulation: PBS with 0.09% sodium azide; pH 7.2
Purification: Affinity chromatography
Data Sheet: TDS
Specific Information
Description: The RMT3-23 monoclonal antibody reacts with mouse CD366 (TIM3), a Th1-specific cell surface protein. The RMT3-23 antibody reacts with CD366 protein expressed by both BALB/c and C57BL/6 strains of mice. CD366, a type I transmembrane protein, contains an immunoglobulin and a mucin-like domain in its extracellular portion and a tyrosine phosphorylation motif in its cytoplasmic portion. CD366 is expressed selectively by differentiated CD4^+Th1 and CD8^+Tc1 cells, but is absent on CD4^+Th2 and CD8^+Tc2 cells. Other hematopoietic cell types, including naive T cells, B cells, macrophages and dendritic cells, do not express CD366, at least at the protein level. CD366 expression is upregulated at a late stage of T cell differentiation on Th1 cells after 3 rounds of in vitro polarization suggesting a role for this molecule in the transport or effector function of Th1 cells rather than a contribution to T cell differentiation. In an experimental autoimmune encephalomyelitis (EAE) model, CD366 was shown to be expressed on most CD4^+ and CD8^+ T cells in the central nervous system at the onset of clinical signs of disease, while less than 2% of CD4^+ cells in the periphery expressed CD366 after immunization.
RMT3-23 has been shown to have functional activity; blocks DC recognition of apoptotic cells and also induces autoantibody production.
Applications Reported: This RMT3-23 antibody has been reported for use in flow cytometric analysis.
Applications Tested: This RMT3-23 antibody has been tested by flow cytometric analysis of CD366 transfected cells. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Purity: Greater than 90%, as determined by SDS-PAGE.
Aggregation: Less than 10%, as determined by HPLC.
Filtration: 0.2 µm post-manufacturing filtered.
Â
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
PRODUCT DETAILS
Host: Rat
Isotype: IgG2a, kappa
Clonality: Monoclonal
Clone: RMT3-23
Reactivity: Ms
Application: Flow Cytometry
Tested Dilution: 1 µg/test
Concentration: 0.5 mg/mL
Storage: 4°C
Formulation: PBS with 0.09% sodium azide; pH 7.2
Purification: Affinity chromatography
Data Sheet: TDS
Specific Information
Description: The RMT3-23 monoclonal antibody reacts with mouse CD366 (TIM3), a Th1-specific cell surface protein. The RMT3-23 antibody reacts with CD366 protein expressed by both BALB/c and C57BL/6 strains of mice. CD366, a type I transmembrane protein, contains an immunoglobulin and a mucin-like domain in its extracellular portion and a tyrosine phosphorylation motif in its cytoplasmic portion. CD366 is expressed selectively by differentiated CD4^+Th1 and CD8^+Tc1 cells, but is absent on CD4^+Th2 and CD8^+Tc2 cells. Other hematopoietic cell types, including naive T cells, B cells, macrophages and dendritic cells, do not express CD366, at least at the protein level. CD366 expression is upregulated at a late stage of T cell differentiation on Th1 cells after 3 rounds of in vitro polarization suggesting a role for this molecule in the transport or effector function of Th1 cells rather than a contribution to T cell differentiation. In an experimental autoimmune encephalomyelitis (EAE) model, CD366 was shown to be expressed on most CD4^+ and CD8^+ T cells in the central nervous system at the onset of clinical signs of disease, while less than 2% of CD4^+ cells in the periphery expressed CD366 after immunization.
RMT3-23 has been shown to have functional activity; blocks DC recognition of apoptotic cells and also induces autoantibody production.
Applications Reported: This RMT3-23 antibody has been reported for use in flow cytometric analysis.
Applications Tested: This RMT3-23 antibody has been tested by flow cytometric analysis of CD366 transfected cells. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Purity: Greater than 90%, as determined by SDS-PAGE.
Aggregation: Less than 10%, as determined by HPLC.
Filtration: 0.2 µm post-manufacturing filtered.
Â
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
